← Back to Search

Monoclonal Antibodies

MCLA-145 for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Merus N.V.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 8 to 12 weeks until study ends, approximately 4 years
Awards & highlights

Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions
  • Cancer
  • Solid Tumors
  • Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 8 to 12 weeks until study ends, approximately 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 8 to 12 weeks until study ends, approximately 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients with Adverse Events and Serious Adverse Events
Number of patients with Dose Limiting Toxicities
Secondary outcome measures
Area under the plasma concentration versus time curve [AUC]
Disease control rate ( DCR)
Duration of response ( DOR)
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: MCLA-145Experimental Treatment1 Intervention
In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 ( every 2 weeks ) until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 at the recommended phase II dose every 2 weeks. The duration of each treatment cycle is 28 days

Find a Location

Who is running the clinical trial?

Merus N.V.Lead Sponsor
7 Previous Clinical Trials
1,247 Total Patients Enrolled
Incyte CorporationIndustry Sponsor
373 Previous Clinical Trials
55,661 Total Patients Enrolled
Ernesto Wasserman, MDStudy DirectorMerus N.V.
3 Previous Clinical Trials
513 Total Patients Enrolled
~19 spots leftby Jul 2025